Literature DB >> 29943994

Multicomponent Reaction Based Synthesis of 1-Tetrazolylimidazo[1,5- a]pyridines.

Santosh Kurhade1, Elmar Diekstra1, Fandi Sutanto1, Katarzyna Kurpiewska2, Justyna Kalinowska-Tłuścik2, Alexander Dömling1.   

Abstract

A series of unprecedented tetrazole-linked imidazo[1,5- a]pyridines are synthesized from simple and readily available building blocks. The reaction sequence involves an azido-Ugi-deprotection reaction followed by an acetic anhydride-mediated N-acylation-cyclization process to afford the target heterocycle. Furthermore, the scope of the methodology was extended to diverse R3-substitutions by employing commercial anhydrides, acid chlorides, and acids as an acyl component. The scope for the postmodification reactions are explored and the usefulness of the synthesis is exemplified by an improved three-step synthesis of a guanylate cyclase stimulator.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29943994      PMCID: PMC6038091          DOI: 10.1021/acs.orglett.8b01452

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


The design and synthesis of new bis-heterocyclic systems are highly appreciated in modern drug discovery to achieve specific drug–receptor interactions.[1] Tetrazole-linked imidazo[1,5-a]pyridine is such an unprecedented class of bis-heterocycles. Individually, the imidazo[1,5-a]pyridine heterocycle is the core of naturally occurring antimicrobial and antineoplastic agent cribrostatin 6[2] as well as many bioactive molecules, for example 5-hydroxytryptamine4 receptor (5-HT4R) antagonists[3] and partial agonists,[4] CB2 agonists,[5] HIV protease inhibitors,[6] thromboxane A2 synthesis inhibitors,[7] and guanylate cyclase stimulators.[8] It has also found applications in material chemistry,[9] and 1,5-disubstituted tetrazoles (1,5-DS-T’s) are bioisosteres of the cis-amide bond of peptides,[10] which are present in various drugs,[11] such as cilostazol and the antibiotics cefonicid and latamoxef.[12] However, a combination of the two well-known imidazo[1,5-a]pyridine and 1,5-DS-T into a bis-heterocyclic systems has not been explored much in medicinal chemistry due to limitations in synthetic feasibility (Figure ). To the best of our knowledge, only Schirok et al. have reported a seven-step synthesis of guanylate cyclase stimulator 3-(2-fluorobenzyl)-1-(1H-tetrazol-5-yl)imidazo[1,5-a]pyridine 9, starting from ethyl 2-(pyridin-2-yl) acetate with 1.8% overall yield (Scheme ).[8] Therefore, developing more practical and efficient synthetic approaches for tetrazole-linked imidazo[1,5-a] pyridines is highly desirable. Our synthetic strategy for such a bis-heterocyclic system involves the Ugi-azide four component reaction (azido-Ugi 4CR)-deprotection to obtain the corresponding pyridin-2-yl(1H-tetrazol-5-yl)methanamine intermediate.[13] The intermediate amine is then converted to tetrazolyl-imidazo[1,5-a]pyridine via an N-acylation–cyclization process (Figure ).[14]
Figure 1

Conceiving the idea.

Scheme 2

Improved Route to the Guanylate Cyclase Stimulator (9)

Conceiving the idea. Thus, we describe the Ugi-azide four-component reaction (azido-Ugi 4CR) mediated synthesis of diverse analogues of 1-tetrazolylimidazo[1,5-a]pyridines. Example 6a (Table , entry 1a) was selected as a model for screening and optimizing the reaction conditions. Equimolar amounts of aldehyde (1, R1 = H), tritylamine 2, isocyanide (3, R2 = benzyl), and azidotrimethylsilane 4 were combined sequentially in MeOH (0.5 M) at room temperature. The corresponding azido-Ugi product 5 was isolated in high yield of 85% after 18 h. Trityl group removal under acidic conditions (4 N HCl/dioxane) gave the (1-benzyl-1H-tetrazol-5-yl)(pyridin-2-yl)methanamine hydrochloride. We then tested the cyclization reaction under different reaction conditions using Ac2O to form 6a. We screened several conditions and varyied reaction parameters such as temperature, base, and Ac2O concentration. To our surprise, no base was required, only Ac2O (0.5 M) and warming (75 °C). A reaction time of 1 h was found to be optimal, with 6a being isolated in quantitative yield. With these optimized conditions in hand, we decided to switch to a one-pot protocol to avoid the isolation of the azido-Ugi intermediate. Here, the generally observed precipitation of trityl Ugi-azides was of great help. The azido-Ugi product 5 was quickly isolated by filtration to remove the solvent methanol and subjected to cyclization without any further purification with 4 N HCl/dioxane (3.0 equiv), Ac2O [0.5 M] at 75 °C for 1 h, affording 6a in 85% overall yield. The reaction proceeds via in situ trityl deprotection followed by Ac2O-mediated N-acylation–cyclization to form 6a. Using the optimized conditions, we next synthesized a series of novel 1-tetrazolyl-3-methylimidazo[1,5-a]pyridines 6b–m in a one-pot, two-step manner (Table , entries 1b–m). The scope of the substrate was evaluated using diverse isocyanides (3) and picolinaldehydes (1). Overall good to excellent yields were obtained. The highest yield of 90% was observed for product 6h (Table , entry 1b). Additionally, a lower yield was observed for the product 6g (65%, entry 1g) and 6i (60%, entry 1d).
Table 1

Substrate Scope of the 1-Tetrazolyl-3-methylimidazo[1,5-a]pyridine Synthesis

Reaction scale 1.0 mmol.

Isolated yield.

Indole N-acylated product was isolated in 15% yield.

Azide–Ugi product (5) was isolated in 62% yield along with tetrazole regioisomeric product 20% yield.

Reaction scale 1.0 mmol. Isolated yield. Indole N-acylated product was isolated in 15% yield. Azide–Ugi product (5) was isolated in 62% yield along with tetrazole regioisomeric product 20% yield. Encouraged by the initial results, we investigated more diverse synthesis by changing the R3-substitutions on tetrazolylimidazo[1,5-a]pyridine core 8 according to our two-step procedure. Accordingly, step 1 involved the trityl deprotection of the azido-Ugi 4CR product 5 under acidic conditions (4 N HCl/dioxane, 10 min) to give the corresponding intermediate pyridin-2-yl(1H-tetrazol-5-yl)methanamine (intermediate a) as a HCl salt.[13] In step 2, intermediate a was N-acylated using 7 as a commercial anhydride or acid chloride in DCM and NEt3 (2.2 equiv) as a base; in the case of acids, classical peptide coupling conditions EDC, HOBt, and NEt3 in DCM were used.[15] Then the in situ formed corresponding N-acyl intermediate (without purification) was subjected to cyclization (1.0 equiv 4 N HCl/dioxane, Ac2O [0.5 M], 120 °C, 1–2 h) after removal of DCM (Table , entries 2a–q). Anhydrides including cyclic glutaric anhydride (entries 2a–c) worked well under the optimized conditions and produced 8a–c in 70–85% overall yield. A diverse set of acid chlorides (entries 2d–i) as the acyl component worked well, and the corresponding products were formed in generally very good yield. We observed a drop in overall yields in the case of acids (40–79%, entries 2k–o) compared to anhydrides and acid chlorides, which may reflect worse coupling yields. In the case of N-Boc-protected amino acids, the corresponding N-acyl products 8m–o (entries 2m–p) were isolated in 40–60% yields. Deborylation was observed in the case of the 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, and 8b was isolated with 70% yield. Thus, Boc and pinacolborane groups were found to be labile under the optimized condition. In case of cyanoacetic acid, a trace amount of product 8q was formed (Table , entry 2q).
Table 2

R3-Substitutions on Tetrazolylimidazo[1,5-a]pyridine

Reaction scale 1.0 mmol.

Isolated yield.

The reaction scale was 5.0 mmol; reaction mixture was heated at 75 °C for 8 h.

Reaction scale 1.0 mmol. Isolated yield. The reaction scale was 5.0 mmol; reaction mixture was heated at 75 °C for 8 h. Several structures have been confirmed by X-ray single-crystal analyses (Figure and Supporting Information). The following interesting motifs could be observed in the solid state: the scaffold in general is flat, and therefore, stocking interactions with neighboring molecules are always observed. In 6b the tetrazole and in 6l the imidazopyridine moieties stack antiparallel. In 6m, a halogen bond with 3.1 Å between the p-Br and N3 of an adjacent tetrazole can be found.
Figure 2

X-ray structures of selected products.

X-ray structures of selected products. A mechanism is proposed in Scheme . The Azido-Ugi reaction mechanism has been documented.[13]
Scheme 1

Proposed Mechanism

Then the azido-Ugi product 5 undergoes N-acylation and forms intermediate 5-I via acid-mediated trityl group deprotection. Further, 5-I undergoes an O-acylation–elimination process and provides nitrilium intermediate 5-II. Attacking the ring nitrogen lone pair of electrons from 5-II leads to the cyclic intermediate 5-III, which upon aromatization leads to the formation of the target product 6 (Scheme ). As an application of the methodology, we could improve upon the synthetic route of the guanylate cyclase stimulator 9 in three simple steps with 76% overall yield, via acid mediated tert-octyl group deprotection[13] of 8j in the final step (Scheme ). After demonstrating the successful synthesis of diverse substituted tetrazolylimidazo[1,5-a]pyridines, we wanted to further demonstrate the scope of the method by synthesizing unsubstituted (R3 = H) examples and explore their postmodification. Examples 8r and 8s were prepared from intermediates 6r and 6s in 74% and 78% yields, respectively, via one pot N-formylation followed by POCl3-mediated dehydration–cyclization process (Scheme ).[16] While attempting the debenzylation of 8r under hydrogenation condition, we observed the selective pyridyl ring saturation product, and 10 was isolated in 98% yield. The interesting low molecular weight free tetrazole 11 building block was obtained in 88% yield by deprotection of the tert-butyl group of 8s under acidic conditions (Scheme ).[17]
Scheme 3

Postmodification Scope

In continuation of exploring the post modification scope, the phthalimide group in 8i was deprotected to form the free amine 12 (90% yield), which was subjected to three different types of reactions: (i) sulfonamide, (ii) urea, and (iii) thiourea formation.[18] All three types of reactions worked well and furnished the desired products 13ac in very good yields of 75–85% (Scheme ). Taken together, we have developed a novel, simple, and efficient two-step method for the synthesis of tetrazolylimidazo[1,5-a]pyridines, a bis-heterocyclic system via the well-known azido-Ugi 4CR reaction, and an unprecedented acetic anhydride mediated post cyclization reaction. Work is ongoing to investigate the further synthetic applications and biological properties of the new compound class.
  21 in total

1.  New insights into cyclobutenone rearrangements: a total synthesis of the natural ROS-generating anti-cancer agent cribrostatin 6.

Authors:  Mubina Mohamed; Théo P Gonçalves; Richard J Whitby; Helen F Sneddon; David C Harrowven
Journal:  Chemistry       Date:  2011-11-14       Impact factor: 5.236

2.  Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Authors:  Dooseop Kim; Liping Wang; Jeffrey J Hale; Christopher L Lynch; Richard J Budhu; Malcolm Maccoss; Sander G Mills; Lorraine Malkowitz; Sandra L Gould; Julie A DeMartino; Martin S Springer; Daria Hazuda; Michael Miller; Joseph Kessler; Renee C Hrin; Gwen Carver; Anthony Carella; Karen Henry; Janet Lineberger; William A Schleif; Emilio A Emini
Journal:  Bioorg Med Chem Lett       Date:  2005-04-15       Impact factor: 2.823

3.  Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.

Authors:  B Wesley Trotter; Kausik K Nanda; Christopher S Burgey; Craig M Potteiger; James Z Deng; Ahren I Green; John C Hartnett; Nathan R Kett; Zhicai Wu; Darrell A Henze; Kimberly Della Penna; Reshma Desai; Michael D Leitl; Wei Lemaire; Rebecca B White; Suzie Yeh; Mark O Urban; Stefanie A Kane; George D Hartman; Mark T Bilodeau
Journal:  Bioorg Med Chem Lett       Date:  2011-03-01       Impact factor: 2.823

Review 4.  Peptide coupling reagents, more than a letter soup.

Authors:  Ayman El-Faham; Fernando Albericio
Journal:  Chem Rev       Date:  2011-08-26       Impact factor: 60.622

5.  Brønsted Acid-Catalyzed Cyanotritylation of Aldehydes by Trityl Isocyanide.

Authors:  Răzvan C Cioc; Peter Schuckman; Hans D Preschel; Tjøstil Vlaar; Eelco Ruijter; Romano V A Orru
Journal:  Org Lett       Date:  2016-07-12       Impact factor: 6.005

6.  Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.

Authors:  N F Ford; L J Browne; T Campbell; C Gemenden; R Goldstein; C Gude; J W Wasley
Journal:  J Med Chem       Date:  1985-02       Impact factor: 7.446

7.  Palladium-catalyzed C-H bond direct alkynylation of 5-membered heteroarenes: a well-defined synthetic route to azole derivatives containing two different alkynyl groups.

Authors:  Fumitoshi Shibahara; Yoshimasa Dohke; Toshiaki Murai
Journal:  J Org Chem       Date:  2012-05-30       Impact factor: 4.354

8.  Antineoplastic agents. 485. Isolation and structure of cribrostatin 6, a dark blue cancer cell growth inhibitor from the marine sponge Cribrochalina sp.

Authors:  George R Pettit; Jeremiah C Collins; John C Knight; Delbert L Herald; Ronald A Nieman; Michael D Williams; Robin K Pettit
Journal:  J Nat Prod       Date:  2003-04       Impact factor: 4.050

9.  Triflic anhydride mediated synthesis of imidazo[1,5-a]azines.

Authors:  Guillaume Pelletier; André B Charette
Journal:  Org Lett       Date:  2013-04-24       Impact factor: 6.005

10.  Combinatorial synthesis of oxazol-thiazole bis-heterocyclic compounds.

Authors:  Siva Murru; Adel Nefzi
Journal:  ACS Comb Sci       Date:  2013-12-09       Impact factor: 3.784

View more
  2 in total

Review 1.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

2.  Synthesis of imidazo[1,5-a]pyridines via cyclocondensation of 2-(aminomethyl)pyridines with electrophilically activated nitroalkanes.

Authors:  Dmitrii A Aksenov; Nikolai A Arutiunov; Vladimir V Maliuga; Alexander V Aksenov; Michael Rubin
Journal:  Beilstein J Org Chem       Date:  2020-11-26       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.